Invivyd (NASDAQ:IVVD) Insider Sells $26,824.32 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 37,256 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the transaction, the insider owned 314,480 shares of the company’s stock, valued at approximately $226,425.60. The trade was a 10.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Tuesday, August 18th, Jill Andersen sold 30,706 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total value of $25,793.04.

Invivyd Stock Down 0.9%

IVVD stock opened at $0.95 on Friday. Invivyd, Inc. has a twelve month low of $0.48 and a twelve month high of $3.07. The firm has a market cap of $280.26 million, a price-to-earnings ratio of -2.88 and a beta of 0.71. The business’s fifty day simple moving average is $0.78 and its two-hundred day simple moving average is $1.22.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. Research analysts expect that Invivyd, Inc. will post -0.51 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on IVVD shares. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Invivyd in a research note on Tuesday. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IVVD. Chicago Partners Investment Group LLC purchased a new stake in shares of Invivyd in the 1st quarter worth approximately $25,000. Courier Capital LLC purchased a new position in Invivyd during the fourth quarter valued at approximately $25,000. Bronte Capital Management Pty Ltd. bought a new position in Invivyd in the fourth quarter worth approximately $27,000. DRW Securities LLC bought a new position in Invivyd in the fourth quarter worth approximately $27,000. Finally, ProShare Advisors LLC bought a new position in Invivyd in the fourth quarter worth approximately $30,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.